IP Library Granted Patent US 8,728,526
Granted Patent B2
US 8,728,526 · App. 11/659,976 · Granted May 20, 2014

Coacervate microparticles useful for the sustained release administration of therapeutic agents

Inventor: Phillip F. Heller (Baltimore, MD)
Assignee: The United States of America, Represented by Secretary of Department of Health and Human Services, NIH
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,728,526
App. No.
11/659,976
Granted
May 20, 2014
Kind
B2
Abstract

The present invention relates to novel microparticles formed using a coacervation process, methods of forming the microparticles, and methods of using the microparticles for the sustained release administration of therapeutic agents.

Claims (6)

1. A composition comprising microparticles having a matrix structure, wherein the matrix structure comprises the reaction product of at least one cationic polymer, at least one anionic polymer, and a binding component, wherein the binding component is distributed throughout the matrix structure of the microparticle, wherein the binding component is one member of a specific binding pair comprising the binding component and a linking moiety, wherein the linking moiety is suitable for linkage with a variety of therapeutic agents; and wherein the composition further comprises a therapeutic agent, wherein the therapeutic agent is linked to the linking moiety, and the therapeutic agent is bound to the microparticles through the specific interaction of the linking moiety with the binding component.

2. The composition of claim 1 , wherein the therapeutic compound is bound to the interior matrix of the microparticle.

3. A composition of claim 1 , wherein the linking moiety molecule is bound to the therapeutic agent by an organic spacer ranging in length from C2 to C24.

4. The composition of claim 1 , wherein at least one cationic polymer is selected from the group consisting of gelatin and albumin and at least one anionic polymer is chondroitin sulfate.

5. The composition of claim 1 , wherein the binding component is an avidin-type molecule and the linking moiety is a biotin-type molecule.

6. The composition of claim 1 , wherein the binding component is a biotin-type molecule and the linking moiety is an avidin type molecule.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE SPELLING OF ASSIGNEE PREVIOUSLY RECORDED ON REEL 019723 FRAME 0617. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF INVENTION DESCRIBED IN PCT/US2005/026257 AND CORRESPONDING US APPLICATION NO 11659976. Recorded Aug 31, 2007
From: HELLER, PHILLIP F.
To: UNITED STATES OF AMERICA, REPRESENTED BY SECRETARY OF DEPARTMENT OF HEALTH AND HUMAN SERVICES, NIH
Reel/Frame 019772/0199 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2007
From: HELLER, PHILLIP F.
To: UNITED STATES OF AMERICA, REPRESENTED BY SECRETARY OF DEPARTMENT OF HEATH AND HUMAN SERVICES, NIH
Reel/Frame 019723/0617 →
Continuity (2)
Provisional Application 60602651 · Aug 19, 2004
Related Publication 20080075778A1 · Mar 27, 2008